Polynucleotides encoding relaxin

US12103955B2 · kind B2 · utility

Assignee

• ModernaTX, Inc. · US

Inventors

• Barry Ticho · Newton, US
• Nadege Briancon-Eris · Wellesley, US
• Zhinan Xia · Wellesley, US
• Athanasios Dousis · Pasadena, US
• Seymour de Picciotto · Boston, US
• Vladimir Presnyak · Manchester, US
• Stephen Hoge · Brookline, US
• Iain McFadyen · Arlington, US
• Kerry Benenato · Sudbury, US
• Ellalahewage Sathyajith Kumarasinghe · Harvard, US

Key dates

• Filing date: Jul 30, 2020
• Grant date: Oct 1, 2024
• Expiry date: May 31, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.